Bank of New York Mellon Corp Has $905,000 Stock Holdings in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

Bank of New York Mellon Corp decreased its holdings in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) by 25.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 108,487 shares of the company's stock after selling 37,365 shares during the quarter. Bank of New York Mellon Corp owned approximately 0.20% of Zevra Therapeutics worth $905,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. MetLife Investment Management LLC boosted its position in Zevra Therapeutics by 8.1% during the third quarter. MetLife Investment Management LLC now owns 22,866 shares of the company's stock worth $159,000 after purchasing an additional 1,717 shares during the period. SG Americas Securities LLC lifted its stake in shares of Zevra Therapeutics by 54.6% in the fourth quarter. SG Americas Securities LLC now owns 23,500 shares of the company's stock worth $196,000 after buying an additional 8,302 shares during the last quarter. Rhumbline Advisers boosted its holdings in shares of Zevra Therapeutics by 18.4% during the 4th quarter. Rhumbline Advisers now owns 68,053 shares of the company's stock worth $568,000 after buying an additional 10,573 shares during the period. Charles Schwab Investment Management Inc. grew its stake in Zevra Therapeutics by 10.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 121,356 shares of the company's stock valued at $842,000 after buying an additional 11,038 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. bought a new position in Zevra Therapeutics in the 4th quarter worth $94,000. Institutional investors own 35.03% of the company's stock.

Insider Transactions at Zevra Therapeutics

In related news, Director John B. Bode purchased 10,000 shares of Zevra Therapeutics stock in a transaction that occurred on Wednesday, March 19th. The shares were acquired at an average price of $7.96 per share, for a total transaction of $79,600.00. Following the transaction, the director now directly owns 40,000 shares in the company, valued at approximately $318,400. This represents a 33.33 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Neil F. Mcfarlane sold 61,273 shares of the stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $7.86, for a total transaction of $481,605.78. Following the sale, the chief executive officer now directly owns 222,060 shares in the company, valued at approximately $1,745,391.60. This represents a 21.63 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 85,773 shares of company stock valued at $674,176. Corporate insiders own 2.40% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the stock. Citigroup restated an "outperform" rating on shares of Zevra Therapeutics in a report on Wednesday, March 12th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $25.00 target price on shares of Zevra Therapeutics in a report on Wednesday, March 12th. HC Wainwright reiterated a "buy" rating and set a $20.00 price target on shares of Zevra Therapeutics in a report on Thursday, March 13th. Canaccord Genuity Group raised their price objective on shares of Zevra Therapeutics from $23.00 to $25.00 and gave the stock a "buy" rating in a research note on Thursday, March 13th. Finally, Guggenheim boosted their target price on shares of Zevra Therapeutics from $20.00 to $22.00 and gave the stock a "buy" rating in a research report on Thursday, March 13th. Eight analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $22.29.

Zevra Therapeutics Price Performance

NASDAQ:ZVRA traded down $0.11 during trading hours on Friday, reaching $7.85. The company had a trading volume of 211,539 shares, compared to its average volume of 590,075. The company has a quick ratio of 2.88, a current ratio of 2.88 and a debt-to-equity ratio of 0.84. The stock has a 50-day moving average of $7.90 and a two-hundred day moving average of $8.20. Zevra Therapeutics, Inc. has a one year low of $4.20 and a one year high of $9.76. The firm has a market capitalization of $424.81 million, a PE ratio of -3.98 and a beta of 1.98.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last posted its earnings results on Tuesday, March 11th. The company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.28). Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%. The firm had revenue of $12.00 million during the quarter, compared to the consensus estimate of $8.93 million. Analysts forecast that Zevra Therapeutics, Inc. will post -1.95 earnings per share for the current year.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.